Nanogen Releases Enterovirus Reagent Employing Newly Patented Hybridization Technology

Jun 15, 2006, 01:00 ET from Nanogen, Inc.

    SAN DIEGO, June 15 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq:  
 NGEN), developer of advanced diagnostic products, announced today that it
 has expanded its product portfolio to include the MGB Alert(TM) ENV
 real-time PCR reagent, designed to detect sequences associated with
 enteroviruses. Prevalent in summer and fall, enterovirus infections cause a
 wide spectrum of diseases and are the most common cause of aseptic
     "According to the Centers for Disease Control, enteroviruses cause an
 estimated 10 to 15 million symptomatic cases a year in the United States,"
 said Howard C. Birndorf, Nanogen chairman and chief executive officer.
 "Enterovirus testing constitutes a segment of the infectious disease
 molecular diagnostics market, which is expected to reach $2.3 billion by
     "Detection of viral infections by real-time PCR is typically faster,
 more sensitive and more specific than through other methods," said
 Birndorf, "and should help reduce the healthcare costs associated with
 enteroviral infections." Aseptic meningitis cases account for tens of
 thousands of hospitalizations every year.
     George E. Buck, chief of microbiology at Norton Healthcare in
 Louisville, KY, finds the MGB Alert ENV product to be "very sensitive and
 easy to use. Physicians at our hospital rely on our results to help them
 diagnose these infections."
     Nanogen's MGB Alert Enterovirus analyte specific reagent (ASR), like
 all MGB Alert products, utilizes novel detection chemistry claimed in U.S.
 Patent 7,045,610, issued to Nanogen May 16. The '610 patent, "Modified
 Oligonucleotides for Mismatch Discrimination," claims the use of modified
 bases to improved hybridization-based diagnostic assays.
     The patented chemistry is employed in most of the company's ASRs and
 research products, enabling laboratories to develop multiple assays with
 universal parameters, which increases the efficiency and throughput of
 clinical testing. The super bases (Super A(TM), Super T(TM), Super G(TM)
 and Super N(TM)) and MGB technology described in '610 allow the use of
 shorter probes with increased sensitivity to mismatches, which have proved
 essential for detecting short conserved sequences of enteroviruses as well
 as other pathogens.
     "Specifically, '610 allows Nanogen to deliver real-time PCR probe and
 primer designs for targets that would be otherwise intractable," said
     About Nanogen, Inc.
     Nanogen's advanced technologies provide researchers, clinicians and
 physicians worldwide with improved methods and tools to predict, diagnose,
 and ultimately help treat disease. The company's products include real-time
 PCR reagents, the NanoChip(R) electronic microarray platform and a line of
 rapid, point-of-care diagnostic tests. Nanogen's ten years of pioneering
 research involving nanotechnology holds the promise of miniaturization and
 continues to be supported for its potential for diagnostic and biodefense
 applications. For additional information please visit Nanogen's website at
     Nanogen Forward-Looking Statement
     This press release contains forward-looking statements that are subject
 to risks and uncertainties that could cause actual results to differ
 materially from those set forth in the forward-looking statements,
 including whether patents owned or licensed by Nanogen will be developed
 into products, whether the patents owned by Nanogen offer any protection
 against competitors with competing technologies, whether products under
 development can be successfully developed and commercialized, whether
 results reported by our customers or partners can be identically
 replicated, and other risks and uncertainties discussed under the caption
 "Factors That May Affect Results" and elsewhere in Nanogen's Form 10-K or
 Form 10-Q most recently filed with the Securities and Exchange Commission.
 These forward-looking statements speak only as of the date hereof. Nanogen
 disclaims any intent or obligation to update these forward-looking

SOURCE Nanogen, Inc.